5.1 Platelets

Specialist in Blood Banking, SBB ASCP

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Eligibility Routes & Credential Maintenance 1.3 Study Strategy for SBB

2 Donors & Collection

2.1 Donor Qualification 2.2 Collection Methods & Adverse Reactions 2.3 Special Donations

3 Processing, Storage & Component QC

3.1 Processing, Testing & Labeling 3.2 Storage, Transport & Expiration 3.3 Blood Component Quality Control

4 Red Cell & Modified Components

4.1 Whole Blood & Red Blood Cells 4.2 Leukocyte-Reduced, Washed, Frozen & Rejuvenated RBCs 4.3 Irradiated Components 4.4 Granulocytes

5 Platelets, Plasma & Cellular Products

5.1 Platelets 5.2 Plasma & Cryoprecipitated AHF 5.3 Apheresis Products & Fractionation Products 5.4 Hematopoietic Progenitors

6 Genetics, ABO & Rh

6.1 Blood Group Genetics & Molecular Inheritance 6.2 ABO & Lewis Systems 6.3 Rh System 6.4 MNS, P1PK/Globoside & Ii

7 Other Blood Groups & Role in Transfusion

7.1 Kell, Kidd, Duffy & Lutheran 7.2 Other Systems & High/Low-Prevalence Antigens 7.3 HLA, Platelet-Specific & Granulocyte Antigens 7.4 Immunogenicity & Antigen Prevalence

8 Immunology Foundations

8.1 Immune Response 8.2 Immunoglobulins 8.3 Antigen-Antibody Interactions 8.4 Complement

9 Physiology, Hemostasis & HDFN

9.1 Physiology of Blood 9.2 Hemostasis and Coagulation 9.3 HDFN Pathophysiology & Detection 9.4 HDFN Treatment & Prevention

10 Cytopenias & Transplantation

10.1 Immune & Nonimmune Anemia 10.2 Thrombocytopenia & Neutropenia 10.3 Solid Organ Transplantation Support 10.4 Hematopoietic Progenitor Cell Transplantation

11 Routine Serologic Testing

11.1 Blood Grouping Tests 11.2 Antibody Detection & Crossmatch 11.3 Antibody Identification & Clinical Significance 11.4 Direct Antiglobulin Testing & Reagents

12 Special Serologic Methods

12.1 Enzymes, Enhancement Media & Lectins 12.2 Adsorptions, Elutions & Titrations 12.3 Cell Separations, Neutralization & Thiol Reagents 12.4 Chloroquine Diphosphate & EDTA-Glycine Acid

13 Molecular Platforms & Serologic QA

13.1 Molecular Blood Group Techniques 13.2 ELISA, Immunofluorescence, Solid Phase & Column Agglutination 13.3 Serologic Quality Assurance

14 Indications, Component Therapy & PBM

14.1 Indications for Transfusion 14.2 Component Therapy 14.3 Blood Administration & Patient Blood Management

15 Adverse Effects of Transfusion

15.1 Immunologic Transfusion Reactions 15.2 Nonimmunologic Reactions 15.3 Transfusion-Transmitted Diseases

16 Apheresis & Extracorporeal Circulation

16.1 Therapeutic Apheresis 16.2 Extracorporeal Circulation

17 Quality, Safety, Math & Instrumentation

17.1 Quality Assessment & Troubleshooting 17.2 Laboratory Safety 17.3 Laboratory Mathematics 17.4 Instrumentation

18 Laboratory Administration (SBB Only)

18.1 Financial Management 18.2 Operations & Information Technology 18.3 Personnel, Education & Training 18.4 Quality Management, Risk & Tissue Management

Key Takeaways Explain This Topic AI

A whole blood-derived platelet concentrate must contain at least 5.5 x 10^10 platelets, while a single apheresis unit must contain at least 3.0 x 10^11 platelets per AABB Standards.

Platelets store at 20-24C with continuous gentle agitation for up to 5 days, or up to 7 days when paired with an FDA-cleared bacterial risk mitigation strategy.

Bacterial contamination is the leading infectious risk of platelet transfusion because room-temperature storage supports bacterial growth that viral testing cannot detect.

Diversion pouches, primary culture, secondary rapid testing, and pathogen reduction technology are the four main bacterial risk mitigation strategies.

The corrected count increment (CCI) adjusts for body size and dose to distinguish immune platelet refractoriness (HLA alloimmunization) from nonimmune consumption.

Last updated: July 2026

Why Platelets Matter on the SBB Exam

Platelet components carry the highest transfusion-transmitted bacterial infection risk of any routine blood product because platelets are stored at room temperature instead of refrigerated or frozen. The SBB exam expects specialist command of platelet manufacturing methods, storage requirements, the bacterial risk mitigation strategies AABB and FDA require, and the corrected count increment (CCI) used to investigate platelet transfusion refractoriness.

Whole Blood-Derived (Random Donor) Platelets

Whole blood-derived platelets, commonly called random donor platelets (RDP) , are prepared from a unit of whole blood using one of two methods: the platelet-rich plasma (PRP) method (a light centrifugation spin isolates platelet-rich plasma, followed by a hard spin that concentrates the platelets) or the buffy coat method (a hard spin first isolates the buffy coat layer, which is then pooled with buffy coats from other units and processed into a platelet concentrate). AABB Standards require a minimum of 5.5 x 10^10 platelets per RDP unit, suspended in roughly 50-70 mL of plasma, with a pH of at least 6.2 at outdate. Because a single RDP unit does not provide a therapeutic adult dose, 4 to 6 units are pooled to reach a typical adult dose of about 3 x 10^11 platelets.

Apheresis (Single-Donor) Platelets

Apheresis platelets, also called single-donor platelets (SDP) , are collected from one donor using an automated cell separator that continuously withdraws whole blood, separates the platelet layer by centrifugation, and returns the remaining red cells and plasma to the donor. AABB Standards require a minimum of 3.0 x 10^11 platelets per apheresis unit - roughly equivalent to a pool of 4 to 6 RDP units - collected from a single donor. Because one apheresis collection replaces multiple RDP donor exposures, SDPs are preferred whenever exposure reduction matters clinically: HLA-matched or crossmatch-compatible platelet support for alloimmunized patients, pediatric and neonatal transfusion, and chronically transfused oncology patients. Leukoreduced apheresis platelets (fewer than 5.0 x 10^6 residual white blood cells per unit) further reduce febrile nonhemolytic reactions, HLA alloimmunization, and CMV transmission risk, and are considered a "CMV-safe" equivalent to CMV-seronegative components.

Feature Random Donor Platelets (RDP) Apheresis Platelets (SDP)
Source Whole blood, pooled 4-6 units Single donor, apheresis
Minimum content 5.5 x 10^10 platelets/unit 3.0 x 10^11 platelets/unit
Donor exposures per adult dose 4-6 donors 1 donor
Typical volume 50-70 mL/unit before pooling 200-400 mL
Best use Routine inventory support Alloimmunized, HLA-matched, exposure-limited patients
Storage Conditions and the Rationale Behind Them

Platelet concentrates are stored at 20-24C with continuous gentle agitation in gas-permeable plastic containers. Agitation and gas-permeable plastic are both essential: platelets are metabolically active and continue aerobic respiration during storage, so the bag must allow oxygen in and carbon dioxide out, and continuous horizontal or flat-bed agitation prevents platelets from aggregating into clumps that would otherwise reduce the viable dose. The standard shelf life is 5 days from collection. FDA guidance permits extending platelet dating to 7 days when the blood center pairs conventional storage with an approved bacterial risk mitigation strategy, discussed below.

Bacterial Contamination: The Dominant Infectious Risk

Because platelets are the only routinely transfused component stored at room temperature, bacterial contamination introduced at phlebotomy (typically skin flora) can proliferate throughout the storage period in a way that is not possible in refrigerated red cells or frozen plasma. Historically, bacterial sepsis from platelet transfusion has exceeded the combined risk of transfusion-transmitted HIV, hepatitis B, and hepatitis C. Four complementary strategies address this risk:

Strategy How It Works

Diversion pouch Discards the first 15-40 mL of collection, which is most likely to carry a skin core/plug contaminated with bacteria

Primary culture Aerobic and anaerobic culture (e.g., automated systems such as BacT/ALERT) performed roughly 24 hours after collection

Secondary rapid testing A rapid immunoassay (e.g., Verax PGD) performed near the end of shelf life, enabling safe extension of dating to 7 days

Pathogen reduction technology (PRT) Amotosalen plus UVA light (INTERCEPT) or riboflavin plus UV light (Mirasol) crosslinks nucleic acids, inactivating bacteria, viruses, and parasites, and can also substitute for gamma irradiation in preventing TA-GVHD

ABO/Rh Considerations for Platelet Selection

Because RDP units carry substantial donor plasma, ABO-identical platelets are preferred , particularly for infants and small-volume recipients, to avoid passive transfer of high-titer anti-A or anti-B between donor and recipient. While platelets themselves do not express Rh antigens, RDP units contain a small volume of residual red cells; an RhD-negative recipient , especially a female of childbearing potential, who receives RhD-positive platelets should be evaluated for Rh immune globulin (RhIG) to prevent Rh alloimmunization.

Assessing Platelet Transfusion Effectiveness: The Corrected Count Increment

The corrected count increment (CCI) adjusts the platelet count rise for body size and dose, allowing comparison across patients and transfusions:

CCI = (post-transfusion count - pretransfusion count, per uL) x body surface area (m^2) / number of platelets transfused (x10^11)

A 1-hour CCI below roughly 5,000-7,500 signals platelet refractoriness - failure to achieve the expected increment. The workup distinguishes immune refractoriness (most often HLA class I alloantibodies from prior transfusion or pregnancy, occasionally platelet-specific [HPA] antibodies) from nonimmune consumption (fever, sepsis, DIC, splenomegaly, amphotericin B). Immune refractoriness is managed with HLA-matched or platelet-crossmatch-compatible apheresis units; nonimmune causes require treating the underlying consumptive process rather than escalating platelet matching.

Worked Example

A 1.8 m^2 patient's platelet count rises from 10,000/uL to 34,000/uL one hour after receiving one apheresis unit containing 3.5 x 10^11 platelets. CCI = (34,000 - 10,000) x 1.8 / 3.5 = 24,000 x 1.8 / 3.5 = 43,200 / 3.5, or approximately 12,340. This CCI is well above the refractoriness threshold, indicating a normal transfusion response.

Common Traps

Confusing the RDP minimum (5.5 x 10^10/unit) with the apheresis minimum (3.0 x 10^11/unit) - they differ by roughly an order of magnitude because one apheresis unit replaces several pooled RDP units.

Assuming refrigeration would be safer for platelets - cold storage activates platelets and shortens their circulating lifespan after transfusion, which is why conventional inventory is stored at room temperature despite the bacterial growth tradeoff.

Forgetting that a low CCI requires distinguishing immune from nonimmune causes before ordering HLA-matched platelets, which are a limited resource.